- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378415
Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression
March 3, 2015 updated by: United States Naval Medical Center, San Diego
The objective of this double-blinded placebo-controlled pilot study is to determine whether a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality has a significant rapid antidepressant effect in the acutely depressed population.
The study will pursue as a primary outcome measure whether a significant reduction in depressive symptoms, as assessed by the BSS and BHS, occurs shortly after administration of ketamine at 40, 80, 120, and 240 minutes.
A secondary outcome measure will be assessed to determine whether this single infusion of ketamine has a sustained reduction in depressive symptoms within 2-weeks post-infusion with a reduction in BDI score.
Suicidal ideation will also be assessed for determination of any reduction and sustained reduction post infusion by assessment of the Beck Suicidal Ideation Scale (BSS), Beck Hopelessness Scale (BHS) and Beck Depression Inventory (BDI) at similar intervals.
Study Overview
Detailed Description
A determination for hospital admittance by a consulting psychiatrist will be made prior to study participation.
Only those persons being admitted to the psychiatric ward will be eligible to enroll in this study.
After consenting to participate in the trial and meeting inclusion criteria for this study (to include a baseline BDI, BSS, and BHS), voluntarily presenting acutely depressed patients, with or without suicidal ideation, will be randomized into two groups and administered standard of care treatment with intravenous ketamine (0.2mg/kg over 1-2 minutes) or standard of care treatment with intravenous normal saline (equal volume to ketamine dose).
All prepared study solutions will be mixed and administered by ED staff and/or nursing staff as per the existing NMCSD ED protocols.
All subjects will be blinded to the treatment given, either an IV bolus dose of ketamine at 0.2-mg/kg over 1-2 minutes or a placebo solution composed of an equal IV bolus dose (by overall volume) of 0.9 normal saline solution will be administered.
Thereafter, all patients will be evaluated clinically with a BSS, BHS, and BDI at 40, 80, 120, and 240 minutes.
All study participants will be monitored medically in the ED for at least the full 240-minute protocol and once declared medically clear, in accordance with standard of care practices by the ED providers, will be transferred to the inpatient psychiatric ward for further monitoring for at least 24-hours prior to discharge from the hospital.
All enrolled patients will be administered another BSS, BHS, and BDI prior to discharge from the hospital.
The length of hospital stay will also be recorded for further analysis, but will not be considered a secondary outcome measure for this study.
Psychiatric determination for discharge from the hospital will be based on clinical assessment, presentation history, and hospital course and is not considered an outcome measure for this study.
All patients included in this study will be re-assessed within 2 weeks with another BSS, BHS, and BDI for determination of sustainability of effects.
Appropriate follow-up care with a psychiatrist will be afforded to all study participants after discharge from the hospital.
Additionally, should any severe adverse side effects develop; the treatment administered to enrolled patients may be un-blinded by a third-party shift medical monitor (i.e. the Charge Nurse) on request from the emergency room provider.
Additionally, given the potential psychotropic effects of ketamine and to assure that patients are sufficiently monitored and appropriately medically cleared, all participants in the study will be required to remain under clinical observation in the emergency room prior to transfer to the psychiatric ward for, at least, the full 4-hour treatment cycle or longer as clinically indicated.
All participants in this study will only be allowed to enroll in this study and undergo this protocol's treatment once.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92134
- Naval Medical Center San Diego
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BSS greater than 4
- BHS greater than 8
- BDI greater than 19
- Ability to give informed consent.
- Active Duty military status.
- Verified negative qualitative pregnancy test.
- All participants must be accepted for psychiatric admission to the hospital PRIOR to consideration for enrollment in this study.
Exclusion Criteria:
- Psychosis or Bipolar Disorder.
- Pregnancy
- Involuntary Status on presentation to the ED.
- UDS positive for illicit drugs of abuse.
- Blood Alcohol level greater than zero.
- Previous enrollees in this treatment protocol will be excluded from repeat participation.
- Any patient brought for command directed psychiatric evaluation.
Specific contraindications to the use of ketamine are as follows and under such circumstances or conditions, personnel with the following should be excluded from participation in this study:
- Patients with elevated intracranial pressure, uncontrolled hypertension, coronary artery disease, aneurysms, thyrotoxicosis, CHF, a recent history of head or eye injury, or angina.
- All personnel in whom a significant elevation of blood pressure would constitute a serious hazard to their overall health and well-being.
- Patients currently utilizing the following medications: conivaptan, Disatinib, peginterferon alfa-2b, quazepam, tocilizumab
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Normal Saline Infusion
A single IV bolus dose of normal saline solution.
|
Normal Saline Infusion
|
Experimental: Subanesthetic IV Bolus Ketamine
a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
|
IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suicidality
Time Frame: Baseline
|
Beck Suicidal Ideation Scale (BSS)
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression
Time Frame: Baseline, 40-minutes, 80-minutes, 120-minutes, 240-minutes, exit at discharge, and at follow-up within 2-weeks
|
Beck Depression Index (BDI)
|
Baseline, 40-minutes, 80-minutes, 120-minutes, 240-minutes, exit at discharge, and at follow-up within 2-weeks
|
Hopelessness
Time Frame: Baseline, 40-minutes, 80-minutes, 120-minutes, 240-minutes, exit at discharge, and at follow-up within 2-weeks
|
Beck Hopelessness Scale
|
Baseline, 40-minutes, 80-minutes, 120-minutes, 240-minutes, exit at discharge, and at follow-up within 2-weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Robert E Lovern, MD, United States Naval Medical Center, San Diego
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
August 15, 2012
First Submitted That Met QC Criteria
March 3, 2015
First Posted (Estimate)
March 4, 2015
Study Record Updates
Last Update Posted (Estimate)
March 4, 2015
Last Update Submitted That Met QC Criteria
March 3, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- NMCSD.2011.0063
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Depression
-
Brigham and Women's HospitalJohns Hopkins University; The University of Texas Health Science Center, Houston and other collaboratorsEnrolling by invitationAcute Suicidal Depression (ASD)United States, Canada
-
AstraZenecaCompletedAcute Bipolar DepressionBrazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
-
Assistance Publique - Hôpitaux de ParisFoundaMental Mental Health Foundation RTRS (France)TerminatedMajor Depressive Episode | Acute Depression
-
Yonsei UniversityNot yet recruitingRespiratory Failure | Respiratory Insufficiency | Hypercapnic Respiratory Failure | Acute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure | Ventilatory Depression | Hypoxemic Respiratory Failure | Respiratory Depression | Hypoxemic Acute Respiratory Failure | Hypercapnic AcuteKorea, Republic of
-
MercyOne Des Moines Medical CenterCompletedDepression | Suicidal Ideation | Depression and Suicide | Depression Severe | Depression AcuteUnited States
-
PLA Rocket Force Characteristic Medical CenterBeijing Municipal Science & Technology CommissionCompletedAcute Stroke Patients With DepressionChina
-
University of California, Los AngelesNot yet recruitingDepression | Stress | Anxiety | Pain, Acute | Pain, Chronic
-
TakedaTerminatedAcute Depressive EpisodeUnited States, Argentina, Chile, Colombia, Mexico
-
Grace Lim, MD, MSUniversity of PittsburghCompletedPostpartum Depression | Pain, Acute | Drug Effect | Opioid Use | Pain, Chronic | Obstetric Pain | Breastfeeding | Obstetric Anesthesia ProblemsUnited States
-
Federal University of Rio Grande do SulMinistry of Health, Brazil; Hospital Moinhos de VentoUnknownDepression | Anxiety | Acute Stress DisorderBrazil
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States